Below are the most recent publications written about "Graft vs Host Disease" by people in Profiles.
-
Holtan SG, Bola?os-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ. Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025 03 10; 43(8):912-918.
-
Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro K, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S. Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival. Blood Adv. 2024 09 10; 8(17):4729-4737.
-
Bi X, Grosso D, Gradone A, Filicko-O'Hara J, McCorkell KA, O'Hara W, Wagner JL, Flomenberg N, Gergis U. A Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant, Results of a Prospective Trial. Transplant Cell Ther. 2024 10; 30(10):1009.e1-1009.e11.
-
Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola?os-Meade J, Abboud R, Briggs AD, Khimani F, Modi D, Newcomb R, Shpall EJ, Bupp C, Spellman SR, Stefanski HE, Shaw BE, Auletta JJ, Devine SM, Jimenez Jimenez AM, Al Malki MM. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. J Clin Oncol. 2024 10; 42(28):3277-3286.
-
Jeurkar C, Leiby B, Rashid S, Gergis U, Grossso D, Carabasi M, Filicko-O'Hara J, O'Hara W, Klumpp T, Porcu P, Flomenberg N, Wagner JL. A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher ?d T cell dose. Eur J Haematol. 2024 Sep; 113(3):283-289.
-
Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Transplant Cell Ther. 2024 07; 30(7):687.e1-687.e13.
-
Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Contreras ME, Fell G, Letai A, Ritz J, Lindsley RC, Soiffer RJ, Antin JH. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 02 27; 8(4):978-990.
-
Little JS, Dul?ry R, Shapiro RM, Aleissa MM, Prockop SE, Koreth J, Ritz J, Antin JH, Cutler C, Nikiforow S, Romee R, Issa NC, Ho VT, Baden LR, Soiffer RJ, Gooptu M. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplant Cell Ther. 2024 02; 30(2):233.e1-233.e14.
-
Maurer K, Ho VT, Inyang E, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Nikiforow S, Antin JH, Wu CJ, Ritz J, Soiffer RJ, Kim HT. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023 08 08; 7(15):3903-3915.
-
Shapiro RM, Kim HT, Ansuinelli M, Guleria I, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar A, Ritz J, Wu CJ, Soiffer RJ, Ho VT, Nikiforow S, Romee R. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023 08 08; 7(15):4080-4088.